Welcome
Support Centre
21 November 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
UKALL XI (92) - Acute lymphoblastic leukaemia trial
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN16757172
Date ISRCTN assigned25/10/2000
Local reference number(s)G8223452
Public titleUKALL XI (92) - Acute lymphoblastic leukaemia trial
Scientific title
AcronymUKALL XI (92)
Disease/condition/study domainLeukaemia
Study hypothesisTo test if CNS disease eradication can be successfully achieved without cranial radiotherapy by using CNS directed chemotherapy, to determine whether the use of high-dose intravenous MTX as part of the CNS therapy will reduce the incidence of systematic relapse, to assess whether a third intensification block of chemotherapy effects disease free survival, to compare by psychometric testing the long term learning and neuropsychological effects of the different CNS treatments.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteriaThey are children including those with Down's syndrome or leukaemia associated chromosome translocations over 1 year and under 15 years with newly diagnosed ALL of any immunologic subtype except B-ALL
Participants - exclusion criteriaChildren with B-ALL and those under 1 year
Patient information material
Anticipated start date01/01/1990
Anticipated end date31/12/1997
Status of trialCompleted
Target number of participantsAdded as of 18/07/2007: 2090 children were recruited.
InterventionsCentral Nervous System (CNS) directed chemotherapy/control
Primary outcome measure(s)Disease-free survival, CNS disease eradication, relapse rates, psychometric test results.
Secondary outcome measure(s)Not provided at time of registration
PublicationsResults: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11328289
Results: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14675406
Results: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11813173
Sources of fundingMedical Research Council (UK)
Sponsor nameMedical Research Council (UK)
Sponsor details20 Park Crescent
London
United Kingdom
W1B 1AL
Sponsor telephone+44 (0)20 7636 5422
Sponsor fax+44 (0)20 7436 6179
Sponsor emailclinical.trial@headoffice.mrc.ac.uk
Sponsor websitehttp://www.mrc.ac.uk
Contact nameDr F Hill
Contact detailsThe Children's Hospital
Ladywood Middleway
Birmingham
United Kingdom
B16 8ET
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN16757172
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central